Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For media inquiries please contact: Michael Sharp. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

The Cannigma

MAY 19, 2021

This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 137

Law Legalization Clinical Trials CBD 137

MMJ Recs

DECEMBER 22, 2023

The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment. These campaigns focus on dispelling myths, highlighting success stories, and educating the public about the science behind cannabis-based treatments.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Project CBD

FEBRUARY 28, 2023

sativa do not naturally contain cannabinoids, but they can become contaminated with CBD from other plant parts during processing. In December 2021, Leafreport, an online CBD resource owned by Empire Media Network, published the results of analyses of 221 CBD products it sent to third-party laboratories for testing. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Media: Liz Melone. CAMBRIDGE, Mass.–(BUSINESS 212-362-1200.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Science also announced a new CTO, Sheldon Borkin , PhD, who joined in September 2021.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

FloridaMarijuana.net

AUGUST 13, 2018

There are a variety of treatment options to help patients cope with and heal from anxiety disorders. Even mainstream media has delved into the medicinal properties of cannabis and the science-based culture that cannabis heals. Cannabis has potential for the treatment of PTSD and substance use disorders. Finnell and Laurie K.

Marijuana 145

Marijuana Patients Clinical Trials Conditions 145

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

CannaMD

MARCH 8, 2021

Prohibiting a medical marijuana treatment center from dispensing marijuana that exceeds a certain potency of tetrahydrocannabinol [p. Revising a provision relating to the potency of tetrahydrocannabinol in edibles dispensed by a medical marijuana treatment center [p.1, 2, line 32]. 2, line 38]. 1, line 12]. 2, line 26]. 2, line 29].

THC 116

THC Research and Development Treatment Patients 116

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Because of this variability in the plant, and because of a lack of standard methods–like chemical analyses of cannabinoids or terpenes–has led to inconsistent scientific results. Types of Research.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

NOVEMBER 16, 2019

Scheme (SAS), Authorised Prescriber Scheme and clinical trials; (b) the suitability of the Pharmaceutical Benefits Scheme for subsidising patient access to medicinal cannabis products; (c) the interaction between state and territory authorities and the Commonwealth, including overlap and variation between. Media Releases.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Media: Liz Melone. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Stern Investor Relations, Inc.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Another finding of the study was that there was minimal crossover between these treatment options, with only three percent of respondents using both marijuana and opioids. Get Started.

Marijuana 87

Marijuana Patients Clinical Trials Data 87

The Cannigma

JUNE 24, 2021

The constant distractions, notifications, and social media outrages of the day can also boost your anxiety and stress, and make it much harder to just live in the moment. Nausea and vomiting — cannabis has long been seen as a potential supportive treatment option for cancer patients undergoing chemotherapy.

CBD 75

CBD Microdosing Edibles Sleep 75

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

SEPTEMBER 1, 2019

I actually produce more natural cannabinoids than the average person – that’s helped me recover from seven strokes,” says Elisabetta Faenza, now CEO of Australian medicinal cannabis company LeafCann. The clinical trials and the standard of production could lead the world.”. But not everyone agrees. “I

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinical trials before they can conclude certain products as GRAS. “To

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. This article analyses media representations of medicinal cannabis in Australian medical publications. Background. 2016 ; Sznitman et al.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JULY 23, 2019

After using Koi’s products, Thurston was given a random drug test by her employer, which came back positive for cannabinoids. It is important that they conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. She lost her job as a result.

Law 40

Law Clinical Trials CBD Edibles 40

SpeedWeed

DECEMBER 28, 2018

Marinol (synthetic THC) has been available by prescription since 1986, and other synthetic cannabinoid drugs are in the works, but Epidiolex is the first plant-derived pharmaceutical to reach the US market. She claims that when Antifa activists publicized her posts to social media and message boards, they took them “out of context.”

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40